Form 4: Vyne Therapeutics CFO Tyler Zeronda Reports Tax-Related Stock Disposal
SEC Form 4 Filing
Tyler Zeronda, CFO of Vyne Therapeutics, reports the disposal of 8,399 common stock shares to cover tax obligations related to vesting restricted stock units on March 31, 2025.
Summary
- On March 31, 2025, Tyler Zeronda, the Chief Financial Officer of Vyne Therapeutics Inc., disposed of 8,399 shares of common stock.
- The disposal was executed to satisfy tax withholding requirements associated with the vesting of restricted stock units.
- The price per share for the transaction was $1.58.
- Following the transaction, Zeronda directly owns 118,493 shares of Vyne Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions for tax purposes, and does not indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of transaction: Disposal of common stock to cover tax obligations. |
| 04/02/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Form 4, Vyne Therapeutics, Tyler Zeronda, CFO, Stock Disposal, Tax Withholding, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.